Makes no sense to present at ESMO if they don’t have new, mature data.
1 Like
data in Corhort 4 is mature
But those data is published before.
not in a scientific conference though or a publication, presented in quarterly meeting this should not violate then the ESMO regulation (read regulation carefully below to see which presentation setting they talk about). Asked @Snoeffelen a question about this, hopefully he will be able to answer us
I hope I am wrong, but out of honesty I feel I need to say what I think
4 Likes
You might be right, but I hope you’re wrong!
But honestly I would be a bit surprised if they don’t have new data to show at ESMO
2 Likes
Just doubt data will be mature after 6 weeks he made the statement knowing that 3 out of the 7 patients did not even pass the safety window then
1 Like
There should be no doubt what so ever that PCIB have efficiacy data from several of the patients in the extension study by now. If those data are not mature enough I will be very disappointed. The first patient was dosed for more than a year ago (for crying out loud). But I have been negatively surprised before - hence I am not taking anything for granted 
5 Likes
They should have been ready after six months. But six months after the last chemo treatment? Or after six months after first round of chemo?
But why go to ESMO with old ‘‘rubbish’’? Does not make sense to me.
4 Likes
Nå kvikner Pcib til og?
Liten konspirasjonsteori, kan det være at noen presser kursen bittelitt opp, så folk skal bruke rettene sine? Råttent spill i tilfelle.
Det har jeg også tenkt på. Men nå begynner det å bli litt sent å kjøre den taktikken synes jeg. De fleste som vil tegne har nok allerede gjort det.
Er nok mange som handla TR siste to timene igår som teller på knappene om det er noen kjappe prosenter å hente.
Jeg blir også veldig skuffet hvis vi ikke får noe data fra den utvidede studien. Men blir ikke overrasket mtp hvor lang tid ting tar i denne bransjen.
I am not sure what the common practice is when it comes to extension studies, I also hope we get at least tumor response data from the patients who have passed the window, remember that as per REK document below 2nd treatment follows after 91 to 133 days (3 months) we had 4 patients recruited by December 2017 so technically by October 2018 all 4 of them should have accumulated minimum 6 months after the second treatment, it is plausible to get tumor response data for these patients at least by the time of the conference (assuming they are alive), however i am not sure if this will be admissible in the conference as the data will not be from all patients recruited, i know too little about the protocols that govern such conferences, so views from experts in the forum are welcomed.
by the way, i have just subscribed with my rights now with even a little extra so hopefully something good comes out of it.
7 Likes
Too bad. Then ESMO in december is next chance too see some fresh data, hoepfully… 
1 Like
Still have hope to see exciting news in ESMO in a couple of weeks, for ESMO december we should definitely get FimaVACC on stage, dont expect any less
2 Likes
You killed my hope!
1 Like
you mean i re-calibrated you hopes 
1 Like
what!!! det har blitt sagt at man kan lese av data ca 1 mnd etter at man har passert safety readout. Mener kjetil har svart det i mail tidligere.
det at 4 av 7 har nådd safetyreadout, ser jeg på som at kun 4 av de 7 var “friske” nok til å gjennomgå 2 behandlinger dvs de har fått kun en behandling fimaporfin (Amphinex) men kan samtidig oppnådd CR for hva vi vet.
1 Like
Kan begynne å lure på hva ledelsen driver med. Dropper den viktigste partnerkonferansen i Asia, men drar med seg hele kostebinderiet til ESMO i oktober for å presentere gamle data?
Håper virkelig jeg tar feil, men har senket forventningene mine til et minimum etter emisjonen.
3 Likes